Non-metastatic castration resistant prostate cancer
Conditions
Interventions
All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within 1 week after enrollment. Visit 1 is at 2 weeks after the treatmen
clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the
Sponsors
Kagawa University Faculty of Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Patients with histologically or cytologically confirmed prostate cancer 2) Patients with history of radical prostatectomy or radiation therapy for radical treatment 3) Patients who receive continuous androgen deprivation therapy using both gonadotropin-releasing hormone (GnRH) agonist and antagonist, or using surgical castration 4) Patients with serum testosterone 1.73 nmol/L (0.50 ng/dL) or less 5) Patients with history of bicalutamide or flutamide at any time after first recurrence confirmed since radical treatment completed 6) Patients with 3 increased PSA test results which measured consecutively at least one week apart during androgen deprivation therapy 7) Patients with serum PSA 1 micrograms/L (1 ng/mL) or more 8) Patients with no confirmed remote metastasis after diagnosis of prostate cancer (excluding lymph nodes metastasis with a minor axis of less than 15 mm which considered to be nonmeasurable in the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1) 9) Patients with asymptomatic prostate cancer 10) Patients with the Eastern Cooperative Oncology Group (ECOG) performance status 0-1 11) Patients with life expectancy of at least 12 months 12) Patients who have signed written informed consent to participate in this study
Exclusion criteria
Exclusion criteria: 1) Patients with history of any chemotherapy (including estramustine phosphate sodium hydrate (JAN)), or treatment with enzalutamide or abiraterone acetate 2) Patients with history of steroid usage as treatment for prostate cancer 3) Patients with history of 5-alpha-reductase inhibitor, estrogen or steroidal antiandrogen within past 4 weeks prior to initial administration of enzalutamide 4) Patients with history of malignant tumor other than prostate cancer within past 3 years 5) Patients with history of seizure or predisposing disease of seizure 6) Patients with severe liver dysfunction 7) Patients with a previous history of hypersensitivity to any component of drugs which will be administered in this study 8) Patients who considered to be inappropriate for the study participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prostate specific antigen-progression-free survival (PSA-PFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Overall survival (OS) 2) Progression-free survival (PFS) 3) Metastasis free survival (MFS) 4) Time to prostate-specific antigen (PSA) progression (TTPP) 5) PSA response rate 6) Time to first use of chemotherapy (TFC) 7) Quality of life assessment using Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales 8) Medication adherence 9) Safety assessment on the incidence and severity of adverse events using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 | — |
Countries
Japan
Contacts
Public ContactMikio Sugimoto
Kagawa University Department of Urology
Outcome results
None listed